04.02.2013 Views

official journal of the patent office - Controller General of Patents ...

official journal of the patent office - Controller General of Patents ...

official journal of the patent office - Controller General of Patents ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

(12) PATENT APPLICATION PUBLICATION<br />

(19) INDIA (21) Application No.: 01017/KOLNP/2005 A<br />

(22) Date <strong>of</strong> filing <strong>of</strong> Application: 30/05/2005 (43) Publication Date: 09/06/2006<br />

(54) Title <strong>of</strong> <strong>the</strong> invention: METHODS AND PRODUCTS RELATED TO TREATMENT AND PREVENTION OF<br />

HEPATITIS C VIRUS INFECTION<br />

(51) International classification : C07K<br />

(31) Priority Document No : 60/421,987<br />

(32) Priority Date : 29/10/2002<br />

(33) Name <strong>of</strong> priority country : US<br />

(86) International Application No and : PCT/US03/005520<br />

Filing Date<br />

: 29/10/2003<br />

(87) International Publication No : WO 04/039829 A2<br />

(61) Patent <strong>of</strong> addition to Application No : NIL<br />

Filed on : N.A.<br />

(62) Divisional to Application No : NIL<br />

Filed on : N.A.<br />

(57) Abstract:<br />

(71) Name <strong>of</strong> Applicant:<br />

COLEY PHARMACEUTICAL GROUP LTD<br />

Address <strong>of</strong> <strong>the</strong> Applicant:<br />

340 TERY FOX DRIVE SUITE 200, KANATA<br />

(OTTAWA) ONTARIO K2K 3A2 CANADA<br />

(72) Name <strong>of</strong> <strong>the</strong> Inventor:<br />

AHLUWALIA NAVNEET K<br />

EFLER SUSAN M<br />

DAVIS HEATHER L<br />

VOLLLMER JORG<br />

Filed U/S 5(2) before The <strong>Patents</strong> (Amendment)<br />

Act, 2005: NO<br />

The invention provides methods for identifying and treating subjects having hepatitis C infections. In some instances, <strong>the</strong> subjects are<br />

those that are non-responsive to non-CpG <strong>the</strong>rapy. Preferably, <strong>the</strong> subjects are treated with C class CpG immunostimulatory nucleic acids<br />

having a semi-s<strong>of</strong>t backbone.<br />

(FIG. - 12)<br />

The Patent Office Journal 09/06/2006 11065

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!